inhibitor of DNA binding 2B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored ID2B profile across patient tissues and cancer cell-line models. ID2B expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, ID2B is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ID2B RNA expression shows 12,496 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight LUSC, KIRC, and CCRCC as cancer lineages where ID2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ID2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ID2B survival associations across molecular data types. ID2B RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ID2B RNA expression–survival associations across cancer types. High ID2B expression shows unfavorable associations in LUSC, KICH, CHOL and SKCM, but favorable associations in BLCA and KIRC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for ID2B RNA expression.
This table summarizes ID2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ID2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ID2B shows lower tumor expression in KICH, PAAD and BRCA and higher tumor expression in KIRC, LUAD and THCA. The KIRC box plot shows higher ID2B RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p = .003).
This table shows molecular features associated with ID2B in patient tissues and cancer cell lines. In patient samples, ID2B shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ID2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
